Wastewater testing during the South African 2022-2023 measles outbreak demonstrates the potential of environmental surveillance to support measles elimination

Nkosenhle Ndlovu[1], Victor Mabasa[1], Chenoa Sankar[1], Nosihle Msomi[1], Emmanuel Phalane[1], Natasha Singh[1], Sipho Gwala[1], Fiona Els[1,2,4], Mokgaetji Macheke[1], Sibonginkosi Maposa[1], and Mukhlid Yousif[¶1,3], Kerrigan M. McCarthy [*¶1,3,4]

[1]Wastewater Genomics, Centre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, Gauteng, South Africa,

[2]Gauteng City-Region Observatory (GCRO), Gauteng, South Africa,

[3]Department of Virology, School of Pathology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, Gauteng, South Africa.

[4] School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, Gauteng, South Africa.

¶These authors contributed equally to this work

*Corresponding author

Address: Centre for Vaccines and Immunology, National Institute for Communicable Diseases, 1 Modderfontein Rd, Sandringham, Johannesburg, 2192, South Africa.

E-mail: kerriganm@nicd.ac.za

Author contributions

Name (Abbreviation)	Contributions	ORCID ID
Nkosenhle Ndlovu (NN)	Data curation, Formal analysis, Investigation, Writing – original draft	
Victor Mabasa (VM)	Conceptualisation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Validation, Writing – review and editing	0000-0002-0564-0344

Chenoa Sankar (CS)	Data curation, Formal analysis, Investigation, Methodology, Software, Writing – review and editing	0009-0007-7869-2026
Nosihle Msomi (NM)	Data curation, Formal analysis, Investigation, Software, Writing – review and editing	0000-0003-0053-0928
Emmanuel Phalane (EP)	Data curation, Investigation, Writing – review and editing	0000-0003-1208-3037
Natasha Singh (NS)	Investigation, Writing – review and editing	0000-0003-3074-8303
Sipho Gwala (SG)	Investigation, Writing – review and editing	0000-0002-8912-5584
Fiona Els (FE)	Writing – review and editing	0000-0002-4169-813X
Mokgaetji Macheke (MM)	Investigation, Writing – review and editing	0000-0002-5179-8230
Sibonginkosi Maposa (SM)	Investigation, Project administration, Resources, Supervision, Writing – review and editing	0000-0003-0575-1420
Mukhlid Yousif (MY)	Conceptualisation, Funding acquisition, Methodology, Supervision Validation, Writing – review and editing	0000-0002-8707-2255
Kerrigan McCarthy (KM)	Conceptualisation, Funding acquisition, Formal analysis, Methodology, Supervision, Validation, Writing original draft, Writing – review and editing	0000-0001-8958-9795

Abstract

Background

Sensitive clinical surveillance and high vaccination coverage are required to meet the WHO 2030 measles elimination target. Whilst wastewater and environmental surveillance (WES) has proven usefulness in polio surveillance, it has not been applied to measles control. We describe the development of digital RT-PCR (RT-dPCR) for detection and quantification of measles virus (MeV) in wastewater, and application to retained concentrated samples obtained from 28 national sentinel SARS-CoV-2 wastewater surveillance sites and 19 localised collection points in a single province before, during and after a measles outbreak of over 2,000 laboratory-confirmed cases.

Methods

We validated a RT-dPCR assay incorporating WHO-recommended primers for detection and differentiation of wild-type and vaccine genotypes. We applied this to retained wastewater samples concentrated by ultrafiltration and stored at -20°C. We compared wastewater findings by district and epidemiological weeks with laboratory-confirmed measles case data obtained from national fever-rash surveillance for districts with adequate surveillance indicators (>2/100,000 non-measles cases)

Findings

Amongst 2,149 wastewater concentrates obtained between 16 February 2021 and 08 March 2024, we identified 43 (2%) samples containing MeV RNA in concentrations ranging from 2,04-6,11 genome copies/mL. MeV genotype A (vaccine strain) was co-detected in wastewater in 6 instances along with non-A (wild-type) genotypes. Comparison of wastewater and clinical fever-rash surveillance data by epidemiological week and district identified 27 district-time instances where at least one positive wastewater sample was identified, of which 14 (52%) districts reported at least one laboratory-confirmed clinical case in that same epidemiological week. Amongst districts with positive wastewater samples, wastewater surveillance detected MeV in 13/27 (48%) time-district pairs when clinical surveillance failed to detect cases. Amongst district-time instances where at least one laboratory-confirmed measles case was detected (N=127), MeV was detected in at least one wastewater sample collected in that same epidemiological week in 14 (11%) districts

Interpretation

Wastewater surveillance may be a useful complementary surveillance tool for identification of districts with ongoing measles circulation. MeV detection rates may be improved by real-time testing to limit RNA degradation and improved concentration and nucleic acid extraction processes. Ongoing wastewater surveillance for MeV should be conducted in order to understand the role of WES in measles control and elimination.

Funding

This work was funded by BMGF (INV-049271)

Introduction

Measles, a highly infectious, vaccine-preventable viral infection, is targeted by the World Health Organization (WHO) for elimination by 2030[1]. Measles incidence and mortality have declined dramatically since the year 2000 due to increasing global vaccination coverage from 72% in 2000 to 83% in 2022, despite a transient decline in 2021 due to the COVID-19 pandemic.[2] Global measles indicators have decreased from 1,072,800 deaths and 145 cases per million in 2000, to 136,200 deaths and 29 cases per million in 2022, of which the largest reduction originates from the WHO-AFRO region (85,417 deaths)[2,3]. Despite these improvements, and recovery of vaccination coverage after the decline during the COVID-19 pandemic, measles is still a leading cause of child death under the age of 5 years in low- and middle-income countries[3]. In support of the 2021-2030 strategic framework for measles and rubella elimination, ongoing global efforts are in place to control viral transmission[1]. These include the provision of two doses of measles vaccine before the age of 5 years as part of the expanded programme of immunisation (EPI)[4], supplementary immunisation activities (SIAs) every 4-5 years where routine vaccination coverage does not achieve 95% coverage, fever-rash surveillance, and rapid, outbreak response[1]. High vaccination coverage and sensitive surveillance systems are vital to achieving elimination.[1]

As measles elimination targets and dates approach, the WHO and national public health authorities rely increasingly on measles surveillance to support program monitoring.[1] However, clinical measles surveillance has several limitations. Firstly, many patients and their care-givers do not seek medical care especially when their clinical presentation is uncomplicated. Secondly, health system factors including clinician awareness, propensity to test and notify, financial allocations for testing, and submission of diagnostic specimens often limit submission of diagnostic specimens[5]. Thirdly, incomplete provision of clinical data (such as date of rash onset and vaccination history) leads to challenges in case classification, contact tracing and outbreak response[6]. Fourthly, urine or throat swabs are less frequently submitted for PCR testing, rendering genomic surveillance challenging as the blood submitted for serology testing infrequently contains measles virus (MeV). [7]

The National Institute for Communicable Diseases (NICD) in Johannesburg, South Africa is one of 86 accredited World Health Organization Global Measles and Rubella Laboratory Network (GMRLN) laboratories and conducts measles testing (IgM and IgG serology, PCR, and sequencing) for South Africa and the southern Africa region.[8] Blood from suspected measles cases (any person with fever, rash and one of cough, conjunctivitis or coryza) is submitted by provincial and district health department staff to the NICD. South African surveillance indicators have consistently achieved more than the required two non-measles fever-rash cases/100,000, except for 2020, when this threshold was only just attained during the SARS-CoV-2 pandemic. [9]

Intermittent measles outbreaks have continued to occur over the last 25 years in South Africa, the largest of which led to over 21,000 laboratory-confirmed cases[9–11]. Most recently, an outbreak of over 1,383 cases commenced in 2022 following apparent importation of the B3 genotype from immediate neighbours.[12,13] The majority of laboratory-confirmed cases were under 15 years of age, with attack rates as high as 31/100,000 in selected age groups and provinces.[12,13] The measles SIA was conducted from February- April 2023 targeting children 1-15 years of age, however only a 54% coverage rate was achieved (personal communication, WHO-AFRO Daudi Peter Manyanga).

Wastewater and environmental surveillance (WES) is presently used to provide highly sensitive surveillance data as part of the WHO-lead global polio elimination initiative (GPEI).[14,15] In 2022 and 2023, following widespread uptake of WES to support SARS-CoV-2 and Mpox surveillance,[16,17] the WHO issued and subsequently updated guidance to support the implementation of WES as a complementary surveillance tool for SARS-CoV-2 outbreak preparedness and response.[18] On the basis of these global experiences, it has been suggested that WES be applied as a surveillance tool for other pathogens targeted for elimination.[19] Whilst a number of groups have developed testing methodologies,[20–23] measles WES has not been implemented as part of routine surveillance or during outbreak response. To date, only Benschkop *et al* detected MeV in 6/56 (10,7%) wastewater samples collected for polio surveillance during a measles outbreak in a vaccine-hesitant community.[24]

In 2020, the NICD expanded polio testing at 18 WES sentinel sites to include SARS-CoV-2 across nine provinces of SA.[25] Over time, and dependent on funding, the number and location of sites changed. Presently, the NICD coordinates a national WES sentinel surveillance network comprising sampling sites at 28 wastewater treatment plants (WWTPs) across nine South African provinces and border transit points, and a network of 19 sampling sites located within the catchment areas of three large WWTPs in the densely populated Gauteng Province.[25] In this paper, we describe the development, optimization and validation of a RT-dPCR assay for detection and quantification of MeV in wastewater, which we applied to retained concentrated wastewater samples from the national sentinel surveillance network and Gauteng catchment sites. As wastewater samples were collected during the ongoing national measles outbreak that began in October 2022, we compared wastewater findings with clinical surveillance data to explore the role of WES as a complementary surveillance tool for programmatic purposes.

Methods and methods

Study design and context

We developed and compared RT-qPCR and RT-dPCR assays that detected and differentiated MeV vaccine and wild-type strains. We applied these and a RT-dPCR assay for PMMoV (to normalize MeV

results relative to fecal contamination) to retained concentrates of wastewater samples collected from the NICD wastewater surveillance network. Presently the network comprises 28 national WWTP sentinel sites and 19 Gauteng sub-catchment inspection holes. Sampling commenced in February 2021 or later, and progressively included all nine SA provinces (Fig 1).

Figure 1. Sampling locations at South African wastewater treatment plants (national sentinel surveillance sites) and in-line sewer sampling sites (sub-catchment areas in City of Tshwane, Johannesburg and Ekurhuleni, inset)

Laboratory methods

Wastewater sample collection, concentration and storage.

Grab samples of one liter in volume were collected monthly, weekly or biweekly from collection sites and were transported at 4°C to the NICD within 24 hours of collection. On receipt, samples were refridgerated at 4°C, and within 24-48 hours, 200mL of raw sewage was centrifuged at 4650g at 4°C for 30 minutes to clarify the sample. Then 70mL of supernatant was centrifuged at 3500g for 15 minutes through a Centricon® Plus-70 centrifugal ultra-filter (Merck Millipore, Tullagreen, Ireland). Material retained in the filter was eluted to a concentrate volume of approximately 1 mL. Concentrates were processed immediately for SARS-CoV-2, and the balance was retained at -20 °C for extraction and PCR once MeV and other assays were developed and validated

Primers and probes for measles and pepper mild mottle virus (PMMoV) detection

Measles- and pepper mild mottle virus (PMMoV)-specific primers and probes were identified from previously described methods (Table 1)[26,27]. We then designed primers and probes to detect MeV genotypes dominant in recent South African outbreaks (B3, D8 and H1) and differentiate these from vaccine strain (genotype A). These were designed by retrieving partial reference genome sequences coding for the N gene of these genotypes from NCBI. Sequence alignments were performed using MAFFT, and BioEdit was used to identify regions of similarity and difference[28]-[29]. Candidate primers were checked for *in silico* specificity, secondary structure formation, GC content and melting temperature using BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi) and OligoAnalyzer Tool (www.idtdna.com). Final sequences and alignments are shown in Figure 2. Wild-type and vaccine probes were created and labeled with ROX and FAM dyes respectively by Integrated DNA Technology (Coralville, Iowa, USA)

163 **Table 1. Primers, probes and source references used for PCR detection of measles virus in**
164 **wastewater samples.**

Target	Genes	Primer name	Sequence (5'-3')	Ref
MeV pan	Nucleocapsid	MVN1139	TGGCATCTGAACTCGGTATCAC	Yoshioka N et al.,2013 (31)
		MVN1213R	TGTCCTCAGTAGTATGCATTGCAA	
		MVNP1163Probe	TAMRA-CCGAGGATGCAAGGCTTGTTTCAGA	
MeV vaccine (genotype A)	Nucleocapsid	VMA168F	GAGATTGGGGGGCAAGGAAGAT	In-house primers
		VMA242R	GCATCACTTGCTCTGCTGGGCC	
		VMA190P	FAM-AGGAGGGTCAAACAGAGTCGA-MGB	
MeV wild-type (genotype non-A)	Nucleocapsid	VMB168F	RRGATTRGGGGGYAAGGARGAY	In-house primers
		VMB242R	RCATCACTTGMTCTGCTRGRYY	
		VMB190P	ROX-AGGAGGGTCARACAGARYCGR	
PMMoV	Unspecified 5' end	PMMOV_END_F	TTC GCA CTG CAC GGA TAA AGT AT	Daire N et al.,2022 (33)
		PMMOV_END_R	GCC CCA AAT TCA TCT GCT GGA A	
		PMMOV_END_M	FAM-ACGCTGTCGCTTTGC	

165

166

167 **Figure 2. Primers and probe design to differentiate measles virus vaccine strain (Edmonston)**
168 **from wild genotypes (B3, D8, and H1).**

169 ***Digital PCR optimisation and determination of limit of detection***

170 We determined the limit of detection (LOD) (defined as the concentration in genome copies/uL of the
171 lowest dilution that is theoretically detectable when using optimized methods) with a single- and duplex
172 RT-dPCR assay using pan-MeV primers with and without rubella virus (Ruv) primers (not described).
173 In triplicate, we serially diluted the measles RNA-positive control provided by the Global Measles
174 Reference Laboratory Network (GMRLN) in 14 two-fold dilutions (neat to 1:16,384) and subjected
175 these to the QIAcuity OneStep Advanced Probe RT-dPCR assay (Qiagen, Hilden, Germany) on
176 QIAcuity® One, 5plex System dPCR platform (Qiagen) using 96-well 8.5k nanoplates. The pan-MeV
177 RT-dPCR master mix contained 3 µL of 4× QIAcuity One-Step Advanced Probe Master Mix, 0.12 µL
178 of 100× One-Step Advanced RT-Mix, 0.6 µL of 20× primer-probe mix MeV (TAMRA), 0.6 µL of 20×
179 RuV primer-probe mix (data not shown) (Cy5) and 1 µL of QIAcuity Enhancer GC. The same master

180 mix set-up was used for vaccine and wild-type primers and probe reactions. Cycling conditions for RT-
181 dPCR were reverse transcription at 50°C for 40 minutes, RT enzyme inactivation at 95°C for 1 minute
182 and 45 cycles of annealing & extension at 60°C.

183 Each RNA dilution of the positive control was also tested using RT-qPCR conducted on the Applied
184 Biosystems® 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using the
185 QIAcuity One-Step Advanced Probe Master Mix. The RT-qPCR master mix contained 4x One-Step
186 Advanced Probe Master Mix 6.25 µL, 100x One-Step Advanced RT-Mix 0.25 µL, 20x primer-probe
187 mix MV (TAMRA) 1.25 µL, 20x primer-probe mix RV (Cy5) 1.25 µL, Enhancer GC 2 µL, RNAse-
188 free water 6 µL.

189 ***Testing of retained wastewater concentrates***

190 Following thawing, retained concentrates were tested in batches of 92 samples. Total nucleic acids were
191 extracted from 200 µL of viral concentrate on the 96 KingFisher Flex Purification System (Thermo
192 Fisher Scientific, Waltham, MA USA) using the MagMAX™ Wastewater Ultra Nucleic Acid Isolation
193 kit (Thermo Fisher Scientific) according to the manufacturers instructions. Briefly, nucleic acids were
194 captured in 520 µL of lysis binding solution before they were washed in 1Ml of Wash 1 and 3 solutions
195 and eluted in 60 µL of elution buffer. We used the formula below to determine the genome copy number
196 per mililitre of the original wastewater sample:

197 $$SC = (C_{rxn} * V_{rxn\ vol.} * (\frac{V_{elute}}{V_{NA}}) * (\frac{V_{total\ conc.}}{V_{conc.\ extracted}})) / V_{sample\ conc.}$$

198 SC = Sample concentration (gc/ml)
199 C_{rxn} = Concentration (gc/µl) obtained from dPCR machine.
200 $V_{rxn\ vol.}$ = Volume (µl) of the PCR reaction.
201 V_{elute}= Total volume (µl) of the extraction elute.
202 V_{NA} = Volume (µl) of nucleic acids used in the PCR reaction.
203 $V_{total\ conc.}$ = Total volume (µl) of the concentrate.
204 $V_{conc.\ extracted}$= Volume (ml) of concentrate used for extraction.
205 $V_{sample\ conc.}$ = Volume of the wastewater sample concentrated.
206

207 ***Differentiation of wild-type and vaccine strains***

208 After identification of MeV positive wastewater samples, we returned to residual retained concentrates
209 from these samples and subjected them to a second extraction and PCR using the QIAcuity® One, 5plex
210 System (Qiagen, Hilden, Germany) as described above using both vaccine and wild-type primers to
211 determine genotype A (vaccine) vs non-genotype A (wild-type)(31). we used the commercially
212 available OMZYTA® MMR live attenuated vaccine (derived from Enders' attenuated Edmonston
213 strain) and RNA from clinical samples collected during an outbreak in South Africa, as positive controls
214 for vaccine and wild-type respectively,

Fever-rash surveillance and diagnostic testing

2.1.2. Fever-rash surveillance

Blood specimens from persons with suspected measles are transported to NICD on ice, and tested for the presence of both measles-specific immunoglobulin M (IgM) antibodies using Euroimmun Anti-Measles virus ELISA (IgM), (Euroimmun AG, Luebeck, Germany). In the absence of vaccination history, NICD surveillance protocols define a laboratory-confirmed case as a positive IgM serologic test for measles in a person with fever, rash and one of cough, conjunctivitis or coryza.

Data analysis

Comparison of dPCR and qPCR results, determination of limit of detection and indicators of fecal contamination

We conducted a regression comparing qPCR Ct thresholds and dPCR genome copies/reaction for each dilution of the positive control in monoplex (MeV) and duplex (MeV plus RuV) to determine the limit of detection (LoD) and to assist with interpretation of low concentrations of MeV detected by dPCR (Fig 1). We determined the presence and concentration of PMMoV in gc/uL, and determined the ratio of MeV:PMMoV

Fig 3. PCR reactions using serial dilutions (1:32 to 1:16,384) of control sequences (obtained from the World Health Organization Global Measles and Rubella Laboratory Network programme) of measles virus (MeV, red) and MeV duplexed with rubella virus (RuV, blue) showing (A) genome copies per microlitre of reaction (vertical axis) by dilution, (dilutions 1:32, 1:64, 1:128, 1:256, 1:512 omitted from the insert) and (B) the cycle threshold (vertical axis) and log of genome copies per microlitre (gc/uL) (horizontal axis). The limit of detection was determined to be 0,365 gc/uL in duplex reaction with RuV.

2.4.2. Comparison of clinical surveillance and wastewater measles testing data

We grouped and tallied the total number and the number of IgM-positive clinical specimens submitted for testing by epidemiological week of sample collection and district of health facility where the case was identified using case-line lists collected as part of national measles fever-rash surveillance. We also grouped and tallied wastewater samples by epidemiological week and district. We merged these clinical and wastewater results by epidemiological week and district and eliminated week-district pairs where no wastewater samples were tested. We defined a 'positive concordant wastewater-clinical pair' as any instance in a given epidemiological-week in a specified district where at least one wastewater sample tested positive for MeV and one case was identified. Conversely we defined a 'negative concordant pair' as one where all wastewater and clinical samples tested negative or no clinical samples were

submitted. The remaining 'discordant' pairs were those where least one case was detected but all wastewater samples were negative, or vice versa. We determined and described the proportion of concordant and discordant week-district pairs, and presented these in two-by-two tables. In concordant instances, we also determined the relationship between the number of measles cases detected and the proportion testing positive with the wastewater levels of MeV in genome copies/mL using simple regression. Given intrinsic weaknesses in measles surveillance (e.g. absent patient health seeking), we investigated and described the discordant instances where MeV was detected in wastewater, but no clinical cases were detected, to identify if clinical cases had been identified in neighbouring districts in the same epidemiological week, or in the same district during the week before or after the positive sample.

Ethics

The protocol for this study was reviewed and approved by the University of the Witwatersrand Human Research Ethics Committee (MM220904)

Results

RT-dPCR assay optimisation and determination of the limit of detection

The manufacture's cycling profile recommended extension for 30s was increased to I minute, and the cycling profile increase from 40 to 45 cycles in order to obtain optimal separation of positive and negative partitions on the RT-dPCR platform. Our in-house primers and assay successfully differentiated clinical MeV strains from vaccine strain (see Supplement). Following optimization of MeV and multiplex MeV and RuV qPCR and dPCR protocols, we determined the relationship between the number positive dPCR partitions and Ct values of qPCR (Fig 1). The limit of detection was determined to be 0,365 gc/uL in duplex reaction with RuV.

Testing of retained concentrates from wastewater samples

A total of 2,149 wastewater concentrates had been stored after processing of grab samples collected across nine provinces between 16 February 2021 and 08 March 2024. Wastewater samples from Limpopo, Mpumalanga, NorthWest and the Northern Cape provinces accounted for 58/2149 (2,6%) as sampling from these sites commenced in November 2023-January 2024, or ceased in May 2022 (Northern Cape Province). Retained concentrates underwent extraction and duplex MeV and RuV (results not presented here) PCR in batches from November 2023 to March 2024. Of the total, 43 samples (2%) tested positive for MeV (Table 2). The majority of wastewater samples were collected in Gauteng province (n=1492), which also had the highest percentage of samples positive for MeV (31, 2,1%, Table 2). No MeV was detected in wastewater from the provinces with the lowest numbers of

tested samples (Table 1). Over the two year period, the majority of positive samples were identified in 2024 (Fig 2, Fig S2). Amongst 42 samples undergoing PCR genotyping, 6 tested positive for both A (vaccine) and non-A (wild-type) genotypes , whilst 36 tested positive for non-A (wild-type) genotype only. All but one sample with vaccine strain detected were collected in Gauteng province, and all were collected at least one month after completion of the national outbreak response SIA. The median MeV concentration amongst positive samples was 2,12 (2,04-2,25) gc/mL, and the median ratio of MeV:PMMoV was $441x10^{-3}$ (range $276x10^{-3}$ -$1528x10^{-3}$).

Table 2: The number of samples tested for MeV by province (and district of Gauteng Province) together with the number and proportion testing positive and the range of genome copies/uL amongst positive samples. All samples tested positive for crAssphage, and the range of quantitative results in genome copies/uL is also provided.

Province	District	Time period		MeV (# tested)	MeV (# positive, %)	MeV gc/mL (median Q1 - Q3)	PMMoV gc/mL (median, Q1-Q3)	Ratio MeV:PMMoV $x10^{-3}$ (median, Q1-Q3)
		Date from	Date to					
Eastern Cape	**Buffalo City and Nelson Mandela Metro**	April 2021	March 2024	187	3 (1.6)	2,12 (2,05-6,4)	404 (346-504)	7,37 (5,33-16,9)
Free State	**Mangaung**	August 2021	March 2024	183	3 (1,6)	2,17 (2,07-4,12)	310 (155-548)	11,17 (6,96-15,37)
Gauteng	**City of Tshwane**	April 2021	March 2024	637	13 (2)	2,12 (2,08-6,11)	1017 (338-2871)	3,27 (1,11-8,04)
Gauteng	**City of Ekurhuleni**	April 2021	March 2024	547	13 (2.4)	2,11 (2,04-2,19)	442 (316-1421)	5,54 (1,43-15,78)
Gauteng	**City of Johannesburg**	April 2021	March 2024	308	5 (1.6)	2,14 (2,11-2,16)	177 (123-199)	11,29 (10,96-17,49)
KwaZulu-Natal	**eThekwini**	August 2021	March 2024	149	5 (3,4)	2,04 (2,04-4,17)	1079 (387-2343	4,08 (0,87-5,27)
North West	**Bojanala**	November 2023	March 2024	22	0	-	1231 (653-1914)	-
Northern Cape	**Namakwa**	August 2021	May 2022	14	0	-	927 (505 - 105)	-
Western Cape	**City of Cape Town**	August 2021	March 2024	72	1 (1.4)	2.1*	1934	1,1
Mpumalanga	**Ehlanzeni**	February 2024	March 2024	10	0	-	616 (217- 821)	-
Limpopo	**Mopani**	February 2024	March 2024	12	0	-	370 (201 - 740)	-
South Africa		April 2021	March 2024	2149	43 (2)	2,12 (2,04-2,25)	441 (276-1528)	5,27 (1,37-15,72)

Fig 4: Epidemiological curve showing the number clinical cases submitted to the National Institute for Communicable Diseases as part of fever-rash surveillance that tested positive for measles IgM (blue bars) and the number of positive wastewater samples (orange or green) by epidemiological week (2021, week 52, to 2024, week 10) from A) the entire South Africa, and B) Gauteng Province

Comparison of clinical surveillance data with wastewater MeV samples.

For each district, the number and proportion of wastewater samples testing positive over the period of observation ranged from 0 to 40% (week 12, 2023 Ekurhuleni Metropole) as seen in Fig 2A&B and S2. We identified 481 epidemiological week-districts where both wastewater samples and clinical diagnostic tests were submitted for surveillance. Amongst week-districts, some districts had multiple wastewater samples (median=2, range 1-19 samples) for a given week from a number of sampling locations (n=1-7), and 357 week-district pairs had more than one positive clinical case per week, ranging from 1-104 cases, with a median of 3 cases per week.

Amongst all week-district pairs, measles was identified in the week-district by both wastewater and clinical surveillance in 2.9% (14) pairs, or, by neither wastewater and clinical surveillance in 343 (71%) of pairs (Table 3). Discordance was observed in the remaining 124 (25.8%) of week-district pairs of which the larger proportion (23.1%) were those with negative wastewater samples in districts where clinical cases were detected. When the time frame for a concordant positive test was broadened to include the presence of clinical cases up to a week before or after a positive wastewater sample, the number of clinical-wastewater time-district pairs where wastewater tested positive and clinical cases were detected increased to 17 (3.5%), whilst the number of time-district pairs where wastewater detected evidence of measles and clinical surveillance failed to detect a case, decreased to 10 (2.1%, Table 3). Amongst concordant wastewater and clinical week-district pairs, there was no discernable relationship between number of cases and measles genome copies/ml in wastewater. Amongst discordant week-district pairs where MeV was detected in wastewater (Table 4), no clinical testing was conducted in nine districts during that week, whilst 1-15 laboratory-confirmed cases of measles were identified in eight of 14 neighbouring districts.

For both wastewater and clinical surveillance, results were considered positive if one or more specimens or samples tested positive in that epidemiological week, and negative if no specimens or samples tested positive. In part A, clinical results were evaluated for the same epidemiological week as wastewater results. In part B, clinical results from the previous, same and next epidemiological week were considered together and compared with wastewater results for a specific week, in order to accommodate for a 7-14 day measles incubation period. No dose-relationship was discernable between the

concentration of MeV detected in wastewater and the number of laboratory-confirmed cases in the same district and epidemiological week (Figure S2)

Table 3. A comparison of wastewater and clinical testing results in the same district and epidemiological week for surveillance conducted between epidemiological week 7, 2021 to epidemiological Week 10, 2024.

Part A: same epidemiological week		**Wastewater Results**		
		Positive	Negative	Total
Clinical Results (IgM)	Positive (IgM)	14 (2.9%)	111 (23.1%)	125
	Negative (IgM)	13 (2.7%)	343 (71.3%)	356
	Total	27	454	481*
Part B: same epidemiological week + clinical results one week before and one after		**Wastewater Results**		
		Positive	Negative	Total
Clinical Results (IgM)	Positive (IgM)	17 (3.5%)	190 (39.5%)	207
	Negative (IgM)	10 (2.1%)	264 (54.9%)	274
	Total	27	454	481

Table 4. **Fever-rash surveillance results for epidemiological weeks and districts where wastewater samples tested positive for measles RNA during epidemiological week 7, 2021 to epidemiological Week 10, 2024.** Epidemiological weeks are designated with the year followed by the week number.

Epidemiological week	**District**	**District under observation**		**Clinical cases in neighbouring districts**		
		Wastewater (positive/total)	**Clinical (IgM +/total)**	**Cases in that week**	**Cases the week before**	**Cases the week after**
2021-W45	Ekurhuleni	1/2	.	0	0	0
2021-W45	Tshwane	1/2	.	0	0	0
2022-W04	Buffalo city	1/2	.	0	0	0
2022-W04	Ekurhuleni	1/2	0/2	2	0	2
2022-W05	Ethekwini	1/2	.	0	0	0
2022-W07	Buffalo city	1/2	.	0	0	0
2022-W18	Tshwane	1/2	0/2	1	0	1
2022-W42	Ekurhuleni	1/2	.	5	4	5
2023-W12	Ethekwini	1/1	0/6	0	1	1
2023-W12	Mangaung	1/2	0/2	4	1	1
2023-W15	Ekurhuleni	1/1	0/1	15	15	7
2023-W20	Johannesburg	1/6	.	9	12	12
2023-W25	Ethekwini	1/1	.	0	0	0
2023-W33	Ekurhuleni	1/5	0/1	7	4	9
2023-W37	Buffalo city	1/4	.	0	0	0

2023-W37	Ekurhuleni	1/10	0/1	2	9	12

4. Discussion

Retrospective testing of retained wastewater concentrates sampled from national and sentinel site surveillance during an ongoing measles outbreak in South Africa detected MeV RNA at copy numbers ranging from 1,97 - 165,8 gc/mL in 43 (2%) of wastewater samples. We observed positive MeV wastewater detections in health districts where no cases were detected. Despite likely RNA decay on account of sample storage, our results illustrate the usefulness of this surveillance modality, and suggest that real-time wastewater surveillance should be conducted together with clinical surveillance to determine the sensitivity of MeV WES and to develop appropriate public health responses to wastewater findings.

For a number of reasons, we believe that detection of MeV in wastewater is representative of measles infections in the catchment area and district and has public health significance. Firstly, MeV is excreted in urine for up to 14 days post vaccination,[30] and will therefore be present in wastewater following wild-type infection. Secondly, viruses from point sources may be detectable in sewage networks for several days after shedding ceases on account of dispersion due to differing gradients, varying flow rates and entrapment in sediment.[31] Thirdly, a positive finding of MeV in wastewater samples even at low copy numbers, is likely to be true, as we demonstrated validity of low copy numbers by testing serial dilutions of positive controls by qPCR and dPCR. Fourthly, MeV has been detected in wastewater in an outbreak context.[24] and in low copy numbers ranging from 2-22 genome copies per milliliter[23]. Fifthly, in our study, laboratory-confirmed measles cases were detected in 14/27 (52%) districts where wastewater tested positive for MeV. MeV negative results in the remaining districts may be explained by the intrinsic limitations of wastewater detection for viral RNA targets (such as viral decay in wastewater matrix, and/or excessive dilution, or timing of sampling), geographical mismatch between case location and wastewater catchment area, or due to prolonged storage of concentrates at -20°C. Lastly, the finding of MeV in wastewater when clinical surveillance fails to identify cases indicates potential for measles outbreaks in our context where vaccination coverage is reportedly less than 95%.

Several limitations are evident from our findings. Sample storage and wastewater concentration methods (ultrafiltration) may have contributed to low viral recovery rates and concentrations[32]. Real time processing and newer concentration-extraction methodologies may enhance detection rates. Despite wastewater sample collection during an outbreak (October 2022 and ongoing) and subsequent

12 week vaccination campaign (February to April 2023), we identified vaccine genotype in only 6 samples, all of which were collected outside the campaign window. RNA decay, and viral dynamics in wild-type infection vs vaccine inoculation, coupled with vaccination of largely immune persons may account for this. This may account for the absence of a dose-response relationship between the concentration of MeV detected in wastewater and the number of laboratory-confirmed cases in the same district and epidemiological week. Lastly, in the context of the coupling of measles and rubella vaccine and combined programmatic goals, there is merit in using a multiplex assays for WES detection of measles and rubella wild-type and vaccine strain detection. Our assays, whilst multiplexed with RuV, did not include vaccine-specific primers and probes for either virus. The inclusion of vaccine-strain-specific primers and probes in the detection assay would facilitate interpretation of results and support immediate public health action. Lastly, there is no available evidence at this moment to support the need for normalizing PCR targets relative to population size using fecal indicators, flow rates or combinations thereof for MeV detection. All our retained samples tested positive for PMMoV at high genome copies/uL, indicating the presence of fecal contamination.

Optimal public health responses to detection of MeV in wastewater in the absence of clinical cases need careful consideration. Following detection of clinical cases, WHO presently recommends case investigation and diagnostic testing, contact tracing with ring vaccination, case finding, and district wide supplementary immunization activities (SIA) if a threshold of cases (two to five cases per health district per month) are identified.[33] Our approach to analysis of our findings, namely a comparison of wastewater and clinical surveillance data at a district level by epidemiological week, is informed by biological parameters of measles infection and WHO guidelines regarding public health responses to measles cases as follows: the incubation period of measles is 1-2 *weeks*, and current surveillance guidelines suggest a threshold of 2-5 cases *per district* in one month before initiating appropriate public health interventions[34]. Therefore, assessment of wastewater detection vs cases per week in a given geographical area may provide forewarning of incubating cases, and support heightened surveillance as a minimum public health response. However, as the sensitivity of WES MeV surveillance becomes clearer, and given the elimination agenda, it may become evident that WES MeV detection should trigger a supplementary immunization activity.

Our findings suggest that real-time WES for measles holds promise to support the global measles and rubella elimination agendas. WES may complement clinical surveillance or be used as the only surveillance modality in contexts with limited access to diagnostic testing. Evaluation of more efficient concentration, extraction and detection methods to improve sensitivity and provide sufficient material for genotyping are desirable. Integration of real-time MeV WES together with clinical surveillance may allow for sensitivity estimations and insight into public health actions following detection of wastewater.

Acknowledgements

We would like to acknowledge the contribution of the NICD Centre for Vaccines and Immunology for use of the polio environmental laboratory, and measles surveillance data (also approved by Wits HREC). We thank the municipal workers, and NICD drivers who collected and transported certain wastewater samples. We thank our sample collectors Lebohang Rabotapi, Lethabo Monametsi, and laboratory technicians Thabo Mangena, Mantshali Motloung for collecting and initial processing of the samples, and our administrator Namhla Madikane for her helpful support and willingness to go to the field when necessary.

Supplementary material

Figure S1. Epidemiological curves by province of South Africa showing the number of IgM positive cases submitted to the National Institute for Communicable Diseases as part of fever-rash surveillance and the number of positive wastewater samples (green) by epidemiological week (2021, week 52, to 2024, week 10)

Figure S2. The number of laboratory-confirmed measles cases (vertical axis) by the number of genome copies of measles virus per millilitre of wastewater (horizontal axis) in wastewater collected from a sample collection point in the district where the measles case was identified (n=43)

References

1. WHO. Measles and Rubella Strategic Framework: 2020-2030. Geneva: WHO; 2020. Available: https://www.who.int/publications/i/item/measles-and-rubella-strategic-framework-2021-2030

2. Dixon MG, Ferrari M, Antoni S, Li X, Portnoy A, Lambert B, et al. Progress Toward Regional Measles Elimination - Worldwide, 2000-2020. MMWR Morb Mortal Wkly Rep. 2021;70: 1563–1569. doi:10.15585/mmwr.mm7045a1

3. Minta AA, Ferrari M, Antoni S, Portnoy A, Sbarra A, Lambert B, et al. Progress Toward Measles Elimination - Worldwide, 2000-2022. MMWR Morb Mortal Wkly Rep. 2023;72: 1262–1268. doi:10.15585/mmwr.mm7246a3

4. Measles vaccines: WHO position paper – April 2017. Releve Epidemiol Hebd. 2017;92: 205–227.

5. Patel MK, Gibson R, Cohen A, Dumolard L, Gacic-Dobo M. Global landscape of measles and rubella surveillance. Vaccine. 2018;36: 7385–7392. doi:10.1016/j.vaccine.2018.10.007

6. Orenstein WA, Hinman A, Nkowane B, Olive JM, Reingold A. Measles and Rubella Global Strategic Plan 2012-2020 midterm review. Vaccine. 2018;36 Suppl 1: A1–A34. doi:10.1016/j.vaccine.2017.09.026

7. Hübschen JM, Gouandjika-Vasilache I, Dina J. Measles. Lancet Lond Engl. 2022;399: 678–690. doi:10.1016/S0140-6736(21)02004-3

8. World Health Organization. Manual for the laboratory-based surveillance of measles, rubella, and congenital rubella syndrome. Geneva, Switzerland; 2018. Available: https://www.who.int/immunization/monitoring_surveillance/burden/laboratory/manual/en/

9. Yousif M, Hong H, Malfeld S, Smit S, Makhathini L, Motsamai T, et al. Measles incidence in South Africa: a six-year review, 2015-2020. BMC Public Health. 2022;22: 1647. doi:10.1186/s12889-022-14069-w

10. McMorrow ML, Gebremedhin G, van den Heever J, Kezaala R, Harris BN, Nandy R, et al. Measles outbreak in South Africa, 2003-2005. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 2009;99: 314–319.

11. Ntshoe GM, McAnerney JM, Archer BN, Smit SB, Harris BN, Tempia S, et al. Measles outbreak in South Africa: epidemiology of laboratory-confirmed measles cases and assessment of intervention, 2009-2011. PloS One. 2013;8: e55682. doi:10.1371/journal.pone.0055682

12. National Institute for Communicable diseases. South African Measles Outbreak Update, 2023. Johannesburg, South Africa: National Institute for Communicable Diseases; 2023 Jun. Available: https://www.nicd.ac.za/south-african-measles-outbreak-update-2023-2-june-2023/

13. National Institute for Communicable diseases. Measles and Rubella Monthly Surveillance Report, 8 April 2024. Johannesburg, South Africa: National Institute for Communicable Diseases; 2024 Apr. Available: https://www.nicd.ac.za/measles-and-rubella-monthly-surveillance-report-08-april-2023/

14. Global polio elimination initiative. Polio Eradication Strategy 2022-2026: Delivering on a Promise. WHO; 2022. Available: https://polioeradication.org/gpei-strategy-2022-2026/

15. O'Reilly KM, Verity R, Durry E, Asghar H, Sharif S, Zaidi SZ, et al. Population sensitivity of acute flaccid paralysis and environmental surveillance for serotype 1 poliovirus in Pakistan: an observational study. BMC Infect Dis. 2018;18: 176. doi:10.1186/s12879-018-3070-4

16. Kilaru P, Hill D, Anderson K, Collins MB, Green H, Kmush BL, et al. Wastewater Surveillance for Infectious Disease: A Systematic Review. Am J Epidemiol. 2023;192: 305–322. doi:10.1093/aje/kwac175

17. Wolfe MK, Yu AT, Duong D, Rane MS, Hughes B, Chan-Herur V, et al. Use of Wastewater for Mpox Outbreak Surveillance in California. N Engl J Med. 2023;388: 570–572. doi:10.1056/NEJMc2213882

18. WHO. Environmental surveillance for SARS-CoV-2 to complement other public health surveillance. Geneva, Switzerland; 2023. Available: https://www.who.int/publications/i/item/9789240080638

19. Shaw AG, Troman C, Akello JO, O'Reilly KM, Gauld J, Grow S, et al. Defining a research agenda for environmental wastewater surveillance of pathogens. Nat Med. 2023;29: 2155–2157. doi:10.1038/s41591-023-02457-7

20. Hayes EK, Gouthro MT, LeBlanc JJ, Gagnon GA. Simultaneous detection of SARS-CoV-2, influenza A, respiratory syncytial virus, and measles in wastewater by multiplex RT-qPCR. Sci Total Environ. 2023;889: 164261. doi:10.1016/j.scitotenv.2023.164261

21. Wu J, Wang MX, Kalvapalle P, Nute M, Treangen TJ, Ensor K, et al. Multiplexed detection, partitioning, and persistence of wild type and vaccine strains of measles, mumps, and rubella viruses in wastewater. medRxiv; 2024. p. 2024.05.23.24307763. doi:10.1101/2024.05.23.24307763

22. Kevill JL, Lambert-Slosarska K, Pellett C, Woodhall N, Richardson-O'Neill I, Pântea I, et al. Assessment of two types of passive sampler for the efficient recovery of SARS-CoV-2 and other viruses from wastewater. Sci Total Environ. 2022;838: 156580. doi:10.1016/j.scitotenv.2022.156580

23. Rector A, Bloemen M, Hoorelbeke B, Ranst MV, Wollants E. Detection of measles virus genotype D8 in wastewater of Brussels capital region, Belgium, March 2024. medRxiv; 2024. p. 2024.04.08.24305478. doi:10.1101/2024.04.08.24305478

24. Benschop KSM, van der Avoort HG, Jusic E, Vennema H, van Binnendijk R, Duizer E. Polio and Measles Down the Drain: Environmental Enterovirus Surveillance in the Netherlands, 2005 to 2015. Appl Environ Microbiol. 2017;83: e00558-17. doi:10.1128/AEM.00558-17

25. NICD. Wastewater-based epidemiology for SARS-CoV-2 surveillance in South Africa - weekly report. Johannesburg, South Africa: NICD; 2024 Epidemiological week. Available: https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/weekly-reports/wastewater-based-epidemiology-for-sars-cov-2-in-south-africa/

26. Yoshioka N, Hagiya H, Deguchi M, Hamaguchi S, Kagita M, Tomono K. Simultaneous and rapid detection method for measles and rubella using single-tube multiplex real-time quantitative RT-PCR. J Infect Chemother Off J Jpn Soc Chemother. 2019;25: 829–831. doi:10.1016/j.jiac.2019.05.005

27. Cantillon D, Roberts AP. Development and evaluation of TaqMan-based, one-step, real-time RT-PCR assays for pepper mild mottle virus detection for near source tracking and wastewater-based epidemiology validation. PloS One. 2022;17: e0278784. doi:10.1371/journal.pone.0278784

28. Yamada KD, Tomii K, Katoh K. Application of the MAFFT sequence alignment program to large data—reexamination of the usefulness of chained guide trees. Bioinformatics. 2016;32: 3246–3251. doi:10.1093/bioinformatics/btw412

29. Carlsblad, C. H T. BioEdit: An important software for molecular biology. GERF bulletin of Biosciences. 2011;2: 60–61.

30. Rota PA, Khan AS, Durigon E, Yuran T, Villamarzo YS, Bellini WJ. Detection of measles virus RNA in urine specimens from vaccine recipients. J Clin Microbiol. 1995;33: 2485–2488. doi:10.1128/jcm.33.9.2485-2488.1995

31. Hovi T, Stenvik M, Partanen H, Kangas A. Poliovirus surveillance by examining sewage specimens. Quantitative recovery of virus after introduction into sewerage at remote upstream location. Epidemiol Infect. 2001;127: 101–106. doi:10.1017/s0950268801005787

32. Rusiñol M, Martínez-Puchol S, Forés E, Itarte M, Girones R, Bofill-Mas S. Concentration methods for the quantification of coronavirus and other potentially pandemic enveloped virus from wastewater. Curr Opin Environ Sci Health. 2020;17: 21–28. doi:10.1016/j.coesh.2020.08.002

33. WHO. Measles outbreak guide. Geneva, Switzerland: WHO; 2022. Available: https://www.who.int/publications/i/item/9789240052079

34. WHO. WHO African Regional measles and rubella surveillance guidelines. WHO AFRO; 2015. Available: https://www.afro.who.int/publications/who-african-regional-measles-and-rubella-surveillance-guidelines-0



Figure X. Primers and probe design to differentiate measles virus vaccine strain (Edmonston) from wild genotypes (B3, D8, and H1).

Figure 2

Figure S1. Sampling locations at South African wastewater treatment plants (national sentinel surveillance sites) and in-line sewers (case-study sub-catchment areas in City of Tshwane, Johannesburg and Ekurhuleni, inset)

Figure 1



Figure 1. Graphs constructed for PCR reactions using serial dilutions (1:32 to 1:16,384) of control sequences (obtained from the World Health Organization Global Measles and Rubella Laboratory Network programme) of measles virus (MeV, red) and MeV duplexed with rubella virus (RuV, blue) showing (A) genome copies per microlitre of reaction (vertical axis) by dilution, (dilutions 1:32, 1:64, 1:128, 1:256, 1:512 omitted from the insert) and (B) the cycle threshold (vertical axis) and log of genome copies per microlitre (gc/uL) (horizontal axis). The limit of quantification was determined to be 0,365 gc/uL in duplex reaction with RuV.

Figure 3



Figure 2. Epidemiological curve showing the number of IgM positive cases submitted to the National Institute for Communicable Diseases as part of fever-rash surveillance (blue bars) and the number of positive wastewater samples (orange or green) by epidemiological week (2021, week 52, to 2024, week 10) from A) the entire South Africa, and B) Gauteng province

Figure 4



Figure S2. Epidemiological curves by province of South Africa showing the number of IgM positive cases submitted to the National Institute for Communicable Diseases as part of fever-rash surveillance and the number of positive wastewater samples (green) by epidemiological week (2021, week 52, to 2024, week 10)



Figure S3. The number of laboratory-confirmed measles cases (vertical axis) by the number of genome copies of measles virus per millilitre of wastewater (horizontal axis) in wastewater collected from a sample collection point in the district where the measles case was identified (n=43)

Figure S2